Viridian Therapeutics, Inc.
NASDAQViridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the work. The story here is a clinical catalyst colliding with a meaningful short base. Short interest has climbed 26% over the past month to 11% of the free float — roughly…
Snapshot as of 7 May 2026
Viridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VRDN — free to start on ORTEX.
Sign up for free →Open VRDN on ORTEX